KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 25,000 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $9.42 per share, with a total value of $235,500.00. Following the completion of the purchase, the insider now owns 5,303,985 shares in the company, valued at $49,963,538.70. This represents a 0.47 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Wednesday, February 12th, Venrock Healthcare Capital Par acquired 100,000 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $9.23 per share, for a total transaction of $923,000.00.
- On Monday, February 10th, Venrock Healthcare Capital Par acquired 4,137 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $9.14 per share, with a total value of $37,812.18.
- On Friday, February 7th, Venrock Healthcare Capital Par acquired 73,649 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $9.29 per share, with a total value of $684,199.21.
- On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $9.22 per share, with a total value of $134,261.64.
- On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $8.76 per share, with a total value of $382,873.32.
KalVista Pharmaceuticals Stock Performance
Shares of KalVista Pharmaceuticals stock opened at $11.49 on Friday. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50. The stock has a market cap of $571.24 million, a PE ratio of -3.16 and a beta of 0.39. The firm has a 50-day moving average of $11.07 and a 200-day moving average of $10.30.
Analyst Ratings Changes
Several equities research analysts recently issued reports on KALV shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. JMP Securities began coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 target price for the company. Jones Trading restated a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday. Finally, Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $24.83.
View Our Latest Stock Report on KALV
Institutional Trading of KalVista Pharmaceuticals
Institutional investors have recently bought and sold shares of the business. Boxer Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $13,467,000. Octagon Capital Advisors LP acquired a new stake in KalVista Pharmaceuticals during the fourth quarter worth approximately $11,604,000. Frazier Life Sciences Management L.P. grew its position in KalVista Pharmaceuticals by 32.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock worth $41,400,000 after buying an additional 1,200,000 shares in the last quarter. Stempoint Capital LP bought a new position in KalVista Pharmaceuticals during the 4th quarter worth $8,409,000. Finally, Vestal Point Capital LP raised its holdings in KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after acquiring an additional 770,000 shares in the last quarter.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
